NCT-06704724

A Phase 1 Open-Label Study of PF-07985045 as a Single-Agent and in Combination with Other Anti-Cancer Agents in Participants with Advanced Solid Tumors

This is a Phase 1 research study testing the new drug PF-07985045 in patients with various types of advanced solid tumors. The study will study the drug both alone and in combination with other anti-cancer agents. The main goals are to determine a safe dose, assess side effects, and understand how the body handles the drug.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06704724

Clinical Trial Site: Columbia

To see all available clinical trials click here.